Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.

Antimicrobial agents and chemotherapy - 1 Nov 2011

Sánchez Almudena, Cabrera Salvador, Santos Dolores, Valverde M Paz, Fuertes Aurelio, Domínguez-Gil Alfonso, García María J

Abstract excerpt

Despite extensive clinical experience with efavirenz (EFV), unpredictable interindividual variabilities in efficacy and toxicity remain important limitations associated with the use of this antiretroviral. The purpose of this study was to determine the factors affecting EFV pharmacokinetics and to develop a pharmacokinetic/pharmacogenetic (PK/PG) model in a Caucasian population of HIV-infected patients. In total,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Alkynes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-HIV Agents

Share to Benzoxazines

Share to Cyclopropanes

Share to HIV Infections

Share to White People

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 21896912
DOI: 10.1128/AAC.00194-11
PMCID: PMC3195031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.PMID 21896912Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Semantic proximity Read ↗

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.Semantic proximity Read ↗

Population Approach to Efavirenz Therapy.Semantic proximity Read ↗

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.Semantic proximity Read ↗

Population pharmacogenetic‐based pharmacokinetic modeling of efavirenz, 7‐hydroxy‐ and 8‐hydroxyefavirenzSemantic proximity Read ↗

Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Semantic proximity Read ↗

Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort.Semantic proximity Read ↗

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsSemantic proximity Read ↗

Impact of pharmacogenetics on CNS side effects related to efavirenz.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.